What is the typical TB-500 dose?
Preclinical research protocols typically use TB-500 doses in the 2-10 mg per dose range, administered subcutaneously on a once- or twice-weekly schedule. The dose range derives from the published tissue-repair literature on full-length thymosin β4 and the synthetic acetylated fragment.
What the research literature says
TB-500 (and full-length thymosin β4) dosing across the preclinical literature typically uses per-dose amounts in the 2-10 mg range. The Bock-Marquette cardiac-repair work (PMID 15565145), the Kleinman dermal-healing review (PMID 27450738), and the Lv limb-ischemia angiogenesis work (PMID 32945357) all used dose tiers in this range across multi-week protocols.
The published protocols typically split the dose schedule into an initial loading phase (higher per-dose amount or more frequent dosing across 1-2 weeks) followed by a maintenance phase (lower per-dose amount or weekly dosing across the remainder of the protocol). The Hinkel cardiac-repair review (PMID 22236126) discusses the loading-vs-maintenance framework in the cardiac-research context.
The dose range is substantially larger than BPC-157’s typical range because TB-500’s mechanism — G-actin sequestration plus integrin-linked kinase activation — operates at higher effective concentrations than receptor-targeted compounds. Researchers running combined BPC-157 + TB-500 protocols typically maintain the per-compound dose tiers (BPC-157 at the lower microgram-per-day range, TB-500 at the milligram-per-week range).
Why this matters in research context
The 2-10 mg per dose tier is the operational anchor for most TB-500 research protocols. The split between weekly and twice-weekly schedules depends on the specific research context — cardiac-repair work often uses twice-weekly dosing across multi-week protocols; tissue-repair work may use weekly dosing across longer protocols. The reconstitution-volume choice should support the chosen per-dose volume without requiring multiple syringe draws per dose.
Related compounds
- TB-500 10mg — the compound covered by this answer
- Wolverine Stack — combined-formulation with BPC-157
Related research questions
- How long is a typical TB-500 cycle?
- How much bacteriostatic water with TB-500?
- What is the half-life of TB-500?
References
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
- Dubé KN et al. Thymosin β4 protein therapy for cardiac repair. Curr Pharm Des 2012;18(6):813-817. [PMID 22236126]
- Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016;102:251-275. [PMID 27450738]
- Lv S et al. Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. Int J Mol Med 2020;46(4):1347-1358. [PMID 32945357]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. TB-500 is sold strictly as a research-grade reagent for laboratory and bench research applications.